© 1995 British Society for Rheumatology
research-article |
METHOTREXATE ACTION IN RHEUMATOID ARTHRITIS: STIMULATION OF CYTOKINE INHIBITOR AND INHIBITION OF CHEMOKINE PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLS
*Division of Rheumatology, University Hospital Inselspital, Bern
Theodor-Kochet-Institute, University of Bern Basel, Switzerlan
Ciba-Geigy Basel, Switzerlan
F.Hoffmann–La Roche Basel, Switzerlan
Correspondence to:
Correspondence to: M. Seitz, Division of Rheumatology, University Hospital, Inselspital, CH-3010 Bern, Switzerland.
This open label study examines whether methotrexate (MTX) treatment modulates ex vivo synthesis of interleukin-1 receptor antagonist (IL-lra), soluble tumour necrosis factor receptors(sTNFR p55 and p75), interleukin-1ß (IL-1ß), tumour necrosis factor 
(TNF-), interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) by peripheral blood mononuclear cells (PBMC} and whether changes reflect clinical response. Significant stimulation of IL-lra and sTNFR p75 as well as inhibition of IL-8 production of PBMC were associated with clinical improvement observed in patients treated with MTX. When defining the characteristics of patients at study entry retrospectively in responders and non-responders a significantly lower ratio of IL-lra :IL-1ß production before and its increase upon treatment was associated with clinical response in 13 patients compared to five patients not responding to MTX. In addition, clinical improvement was associated with decreased synthesis of IL-1ß, TNF- and IL-8 induced by bacterial lipopolysaccharide, IL-1 and IL-1ß in PBMC in vitro. These findings suggest that MTX therapy reverses the inflammatory type of rheumatoid arthritis (RA) blood mononuclear cells by stimulating cytokine inhibitor production while inhibiting inflammatory cytokine release at the same time. This may explain the powerful anti-inflammatory properties of low-dose MTX as observed in most RA patients. Pretreatment determination of the IL-lra: IL-1ß ratio in PBMC may be predictive with regard to a favourable therapeutic response and therefore may be useful for the selection of RA patients to be treated with MTX.
KEY WORDS: Methotrexate, Cytokines, Cytokine inhibitors, Rheumatoid arthritis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J K Franz and G-R Burmester The needle and the damage done Ann Rheum Dis, June 1, 2005; 64(6): 798 - 800. [Full Text] [PDF]
|
|
|
|
|
|
S B Cohen, L W Moreland, J J Cush, M W Greenwald, S Block, W J Shergy, P S Hanrahan, M M Kraishi, A Patel, G Sun, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate Ann Rheum Dis, September 1, 2004; 63(9): 1062 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Gerards, S. de Lathouder, E. R. de Groot, B. A. C. Dijkmans, and L. A. Aarden Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis Rheumatology, October 1, 2003; 42(10): 1189 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Podolin, B. J. Bolognese, J. J. Foley, D. B. Schmidt, P. T. Buckley, K. L. Widdowson, Q. Jin, J. R. White, J. M. Lee, R. B. Goodman, et al. A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit J. Immunol., December 1, 2002; 169(11): 6435 - 6444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M CUTOLO, A SULLI, C PIZZORNI, B SERIOLO, and R H STRAUB Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis Ann Rheum Dis, August 1, 2001; 60(8): 729 - 735. [Full Text] [PDF]
|
|
|
|
|
|
M. Seitz and J.-M. Dayer Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment Rheumatology, June 1, 2000; 39(6): 637 - 645. [Abstract] [Full Text] [PDF]
|
|